CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 117 enrolled
Drug / intervention
Naproxen Sodium (Aleve, BAY117031) +1 moredrug
Likely dose
Naproxen Sodium (Aleve, BAY117031) 220 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02229461
NCT02229461Phase 1Completed
CompareCT.gov

A Randomized, Open Label, Parallel Group Study to Investigate the Effects on Serum Thromboxane by the Addition of Naproxen Sodium to Aspirin Therapy Versus Aspirin Therapy Alone

Bayer·interventional·Posted Sep 1, 2014·Updated Jul 15, 2016

In Brief

A Phase 1 clinical trial evaluating Naproxen Sodium (Aleve, BAY117031) and Acetylsalicylic Acid (Aspirin, BAYE4465) for Hematology. Completed, enrolled 117 participants across 1 site.

Detailed Summary

To determine if administration of naproxen sodium 220 mg maintains the platelet inhibitory effect of a low dose Immediate Release Aspirin (IR ASA) regimen.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHematology
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 1, 2014
Enrollment StartFeb 1, 2015
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 11.8 years ago

Interventions

Naproxen Sodium (Aleve, BAY117031)drug

Naproxen sodium 220 mg qd or bid

Acetylsalicylic Acid (Aspirin, BAYE4465)drug

ASA 81 mg qd